keyboard_arrow_right
Search & Filter keyboard_arrow_right
keyboard_arrow_left Hide
CONFERENCE DAY ONE
keyboard_arrow_leftSearch & Filter
search
Streams
Formats
CONFERENCE DAY ONE
search
Streams
Formats
7:30am - 8:00am30 mins
Registration
8:00am - 8:15am15 mins
Conference Opening and Welcome
- Anthony Davies - Founder & CEO, Dark Horse Consulting, USA
8:15am - 8:45am30 mins
Solid Tumours – New Modalities, Combination Therapies and Novel Cancer Treatment
Virus Specific T Cells as Platform for Solid Tumor Immunotherapy
- Richard Hopkins - Research Director, R&D department, Tessa Therapeutics, Singapore
8:45am - 9:15am30 mins
Solid Tumours – New Modalities, Combination Therapies and Novel Cancer Treatment
Allo CAR T targeting CD70 for the treatment of renal cell carcinoma
- Siler Panowski - Associate Director, Solid Tumors, Allogene Therapeutics, USA
9:15am - 9:45am30 mins
Solid Tumours – New Modalities, Combination Therapies and Novel Cancer Treatment
Safety and efficacy of TCR-mimic technology in hematologic and solid cancers, from discover concept to in-vitro and in-vivo validation to clinical results
- Jessica Lee - Corporate Development Manager, Eureka
9:45am - 10:30am45 mins
Morning Coffee and Networking
10:30am - 11:00am30 mins
Solid Tumours – New Modalities, Combination Therapies and Novel Cancer Treatment
Repurposing Endogenous Immune Pathways to Tailor and Control Chimeric Antigen Receptor T-cell Functionality
- Julien Valton - Innovation Team Leader, Cellectis, USA
11:00am - 11:30am30 mins
Solid Tumours – New Modalities, Combination Therapies and Novel Cancer Treatment
Developing an Allogeneic TCR-T Approach based on Gamma Delta T Cells
- Ali Mohamed - VP, CMC, Immatics, USA
11:30am - 12:00pm30 mins
Solid Tumours – New Modalities, Combination Therapies and Novel Cancer Treatment
dCas9/CAR T platform: Efficacy and safety all-in-one therapy
- Zhifen Yang - Senior Scientist, Refuge Biotech
12:00pm - 12:30pm30 mins
Solid Tumours – New Modalities, Combination Therapies and Novel Cancer Treatment
Nanoparticle Mediated Non-Viral Gene Delivery to Enable Development of Next Gen T Cell Therapies
- Samuel Clarke - Director of R&D, Precision NanoSystems Inc., Canada
12:30pm - 1:45pm75 mins
Lunch break and networking
1:45pm - 2:15pm30 mins
Safety Switches, Synthetic Biology and Mechanisms to Improve Safety and Efficacy
Improving the in vivo persistence and function of tumor-specific T-cells
- Cliona Rooney - Professor, Baylor College of Medicine
2:15pm - 2:45pm30 mins
Safety Switches, Synthetic Biology and Mechanisms to Improve Safety and Efficacy
Small molecule CAR T cell control: making the Switch
- Stephen Santoro - Principal Scientist, Kite Pharma, a Gilead Company, USA
2:45pm - 3:15pm30 mins
Safety Switches, Synthetic Biology and Mechanisms to Improve Safety and Efficacy
Genetic modification of T cells to express CD19-specific CAR in two days
- Harjeet Singh - Instructor, Department of Pediatrics, UT MD Anderson Cancer Center, USA
3:15pm - 4:00pm45 mins
Afternoon Coffee
4:00pm - 4:30pm30 mins
Safety Switches, Synthetic Biology and Mechanisms to Improve Safety and Efficacy
Triumvira Immunologics Case Study
- Jonathan Bramson - Co-Founder & CSO, Triumvira Immunologics, Inc.
4:30pm - 5:30pm60 mins
Cocktail Reception in Exhibit & Poster Hall
Filter
Streams
Formats